Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1611-1620 of 10637

Edit search filters
  1. Technology-enhanced Transitional Care for Rural Palliative Care Patients: A Pilot Study

    Mankato, MN, Rochester, MN

  2. EndoMAXX EVT Compared to EndoMAXX

    Rochester, MN

  3. Sofosbuvir/GS-5816 Fixed-Dose Combination in Adults with Chronic HCV Infection and Child-Pugh Class B Cirrhosis

    Scottsdale/Phoenix, AZ

  4. Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation

    Rochester, MN

  5. A Phase I Study of TAS-102 in Patients with Advanced Solid Tumors with Renal Impairment

    Scottsdale/Phoenix, AZ

  6. Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients with Refractory Advanced Solid Tumors

    Rochester, MN

  7. A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression

    Rochester, MN

  8. Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  9. Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

    Rochester, MN

  10. MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

    Rochester, MN

.

Mayo Clinic Footer